Blandine Bève

Eprenetapopt Plus Azacitidine in <i>TP53</i>-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)

Thomas Cluzeau, Marie Sébert, Ramy Rahmé et al. · Journal of Clinical Oncology · 2021 · 268 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Azacitidine in untreated acute myeloid leukemia: A report on 149 patients

Sylvain Thépot, Raphaël Itzykson, Valérie Seegers et al. · American Journal of Hematology · 2013 · 101 citations · Full text

Medicine, Hematology, Pharmacology +15

APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myélodysplasies (GFM)

Thomas Cluzeau, Marie Sébert, Ramy Rahmé et al. · Blood · 2019 · 65 citations

Medicine, Oncology, Pharmacotherapy +16

Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience

Lionel Adès, Sylvie Chevret, Stéphane de Botton et al. · Leukemia · 2004 · 63 citations

Medicine, Hematology, Oncology +15

Incidence of <scp>ATRX</scp> mutations in myelodysplastic syndromes, the value of microcytosis

Charles Herbaux, Nicolas Duployez, Catherine Badens et al. · American Journal of Hematology · 2015 · 19 citations · Full text

Medicine, Genetics, Hematology +11